Takeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – AbbVie’s Humira – in severely active ulcerative colitis. The results are ...

What you’ll pay for Entyvio depends on your insurance coverage, your treatment plan, and potential coupons and savings programs. For example, Entyvio’s cost with Medicare varies based on your specific ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients with ulcerative colitis were more likely to ...

Entyvio conferred superior clinical remission and mucosal healing compared with Humira among patients with moderately to severely active ulcerative colitis, according to results of a phase 3b ...

Entyvio is a brand-name prescription medication known as a biologic. Its active ingredient is called vedolizumab. Generic versions of biologic medications are called biosimilars. But only the ...

Takeda has new clinical data on a subcutaneous formulation of its Entyvio drug in Crohn’s disease, expanding the potential of the drug beyond ulcerative colitis. Top-line results from the VISIBLE 2 ...

Credit: Takeda. The approval was based on data from the phase 3 VISIBLE 2 trial. Results showed 48% of patients treated with vedolizumab SC were in clinical remission at week 52 compared with 34% of ...

Takeda says it has late-stage trial results showing the benefit of an investigational subcutaneous formulation of Entyvio to patients with ulcerative colitis. Takeda says it has late-stage trial ...

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a confirmatory ...

The U.S. Food and Drug Administration today approved Entyvio (vedolizumab) injection to treat adult patients with moderate to severe ulcerative colitis and adult patients with moderate to severe Crohn ...

Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...